Myostatin and insulin-like growth factor-1 in hypertensive heart disease: A prospective study in human heart donors

Journal of Hypertension

Volumn 33, Issue 4, 2015, Pages 851-859

  Fernández Solà, Joaquim ^a   Borrisser Pairó, Francesc ^a   Antú Nez, Emilia ^a   Tobías, Ester ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cardiac remodelling; Cardiomyopathy; Hypertension; IGF 1; Myostatin

Indexed keywords

MYOSTATIN; SOMATOMEDIN C; MSTN PROTEIN, HUMAN;

ADULT; CARDIOMYOPATHY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE INJURY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; ORGAN DONOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; AGED; ALCOHOLISM; APOPTOSIS; CASE CONTROL STUDY; COMPLICATION; DONOR; GENE EXPRESSION; HEART DISEASES; HEART MUSCLE; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALCOHOLISM; APOPTOSIS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HEART DISEASES; HUMANS; HYPERTENSION; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MYOCARDIUM; MYOSTATIN; PROSPECTIVE STUDIES; TISSUE DONORS;

EID: 84938906407     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000493     Document Type: Conference Paper

References (49)

1. Lip GYH, Felmeden DC, Li-Saw-Hee FL, Beevers DG. Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur Heart J 2000; 21:1653-1665.
2. Diamond JA, Phillips RA. Hypertensive heart disease. Hypertens Res 2005; 28:191-202.
3. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KL. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562.
4. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
5. Diez J, Frohlich ED. A translational approach to hypertensive heart disease. Hypertension 2010; 55:1-8.
6. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008; 358:1370-1380.
7. Diez J. Towards a new paradigm about hypertensive heart disease. Med Clin N Am 2009; 93:637-645.
8. Deschepper CF, Boutin-Ganache I, Zahabi A, Jiang Z. In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. Hypertension 2002; 39:332-336.
9. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, Niederle B. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocr Metab 1997; 82:106-112.
10. Fazio S, Cittadini A, Cuocolo A, Merola B, Sabatini D, Colao A, et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocr Metab 1994; 79:441-446.
11. Joulia-Ekaza D, Cabello G. Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res 2006; 312:2401-2414.
12. McKoy G, Bicknell KA, Patel K, Brooks G. Developmental expression of myostatin in cardiomyocytes and its effect on foetal and neonatal rat cardiomyocyte proliferation. Cardiovasc Res 2007; 74:304-312.
13. Fernandez-Sola J, Lluis M, Sacanella E, Estruch R, Antunez E, Urbano-Marquez A. Increased myostatin activity and decreased myocyte proliferation in chronic alcoholic cardiomyopathy. Alcohol Clin Exp Res 2011; 35:1-10.
14. Wang L, Ma W, Markovich R, Chen J-W, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 1998; 83:516-522.
15. Dean RG, Bach LA, Burrell LM. Upregulation of cardiac insulin-like growth factor-I receptor by ACE inhibition after myocardial infarction: potential role in remodeling. J Histochem Cytochem 2003; 51:831-839.
16. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 1995; 30:825-834.
17. Leroith D, Werner H, Beitner-Johnson D, Roberts AT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16:143-163.
18. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999; 31:2049-2061.
19. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16:3-34.
20. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 1995; 55:303-306.
21. Fan J, Char D, Kolasa AJ, Pan W, Maitra SR, Patlak CS, et al. Alterations in hepatic production and peripheral clearance of IGF-I after endotoxin. Am J Physiol-Endoc M 1995; 269:E33-E42.
22. Chu CH, Lo JF, Hu WS, Lu RB, Chang MH, Tsai FJ, et al. Histone acetylation is essential for ANG-II-induced IGF-IIR gene expression in H9c2 cardiomyoblast cells and pathologically hypertensive rat heart. J Cell Physiol 2012; 227:259-268.
23. Lee S-D, Chu C-H, Huang E-J, Lu M-C, Liu J-Y, Liu C-J, et al. Roles of insulin-like growth factor II in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation.Am J Physiol Endocrinol Metab 2006; 291:E306-E314.
24. Lang CH, Frost RA, Svanberg E, Vary TC. IGF-I/IGFBP-3 ameliorates alterations in protein synthesis, eIF4E availability, and myostatin in alcohol-fed rats. Am J Physiol Endocrinol Metab 2004; 286:E916-E926.
25. Zhang B, Turdi S, Li Q, Lopez FL, Eason AR, Anversa P, Ren J. Cardiac overexpression of insulin-like growth factor 1 attenuates chronic alcohol intake-induced myocardial contractile dysfunction but not hypertrophy: Roles of Akt, mTOR, GSK3, and PTEN. Free Radical Biol Med 2010; 49:1238-1253.
26. Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LFS, et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 2008; 159:389-397.
27. Andronico G, Mangano MT, Nardi E, Mule G, Piazza G, Cerasola G. Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J Hypertens 1993; 11:1097-1101.
28. Diez J, Laviades C, Martinez E, Gil MJ, Monreal I, Fernandez J, Prieto J. Insulin-like growth factor binding proteins in arterial hypertension: relationship to left ventricular hypertrophy. J Hypertens 1995; 13:349-355.
29. Borrisser-Pairo F, Antunez E, Tobias E, Fernandez-Sola J. Insulin-like growth factor 1 myocardial expression decreases in chronic alcohol consumption. Regen Med Res 2013; 1:3; doi:10.1186/2050-490X-1-3.
30. Vriz O, Piccolo D, Cozzutti E, Milani L, Gelisio R, Pegoraro F, et al. The effects of alcohol consumption on ambulatory blood pressure and target organs in subjects with borderline to mild hypertension. Am J Hypertens 1998; 11:230-234.
31. Fatjo F, Fernandez-Sola J, Lluis M, Elena M, Badia E, Sacanella E, et al. Myocardial antioxidant status in chronic alcoholism. Alcohol Clin Exp Res 2005; 29:864-870.
32. Fernandez-Sola J, Fatjo F, Sacanella E, Estruch R, Bosch X, Urbano-Marquez A, Nicolas J-M. Evidence of apoptosis in alcoholic cardiomyopathy. Hum Pathol 2006; 37:1100-1110.
33. Ector H, Lancellotti P, Roberts WC, Wenger NK, Moss AJ, Smith ER, et al. A statement on ethics from the HEART group. JACC Cardiovasc Imaging 2008; 1:410-412.
34. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
35. de Vries J, Lemmens P, Pietinen P, Kok F. Assessment of alcohol consumption. In: MacDonald I, editor. Health issues related to alcohol consumption. Volume 2, 2nd ed. Oxford, UK: Blackwell Science; 1999. pp. 28-62.
36. Fernandez-Sola J, Estruch R, Grau JM, Pare JC, Rubin E, Urbano-Marquez A. The relation of alcoholic myopathy to cardiomyopathy. Ann Intern Med 1994; 120:529-536.
37. Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau JM, Mont L, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989; 320:409-415.
38. Goldman L, Hashimoto B, Cook E, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981; 64:1227-1234.
39. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials: a report from the american society of echocardiography's guidelines and standards committee and the task force on echocardiography in clinical trials. J Am Soc Echocardiog 2004; 17:1086-1119.
40. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59:551-571.
41. Jin X, Xia L, Wang L, Shi J, Zheng Y, Chen W, et al. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics 2006; 6:2326-12326.
42. Niemela O, Parkkila S, Worrall S, Emery PW, Preedy VR. Generation of aldehyde-derived protein modifications in ethanol-exposed heart. Alcohol Clin Exp Res 2003; 27:1987-1992.
43. Ren J, Wold LE. Mechanisms of alcoholic heart disease. Ther Adv Cardiovasc Dis 2008; 2:497-506.
44. Shyu K-G, Ko W-H, Yang W-S, Wang B-W, Kuan P. Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovasc Res 2005; 68:405-414.
45. Gonzalez A, Fortuno MaA, Querejeta R, Ravassa S, Lopez B, Lopez N, Di?ez J. Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res 2003; 59:549-562.
46. Wagner KR, Liu X, Chang X, Allen RE. Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci U S A 2005; 102:2519-2524.
47. Yang W, Zhang Y, Ma G, Zhao X, Chen Y, Zhu D. Identification of gene expression modifications in myostatin-stimulated myoblasts. Biochem Biophys Res Commun 2005; 326:660-666.
48. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol-Heart C 2005; 289:H8-H16.
49. Fazio S, Palmieri EA, Affuso F, Cittadini A, Castellano G, Russo T, et al. Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. J Clin Endocr Metab 2007; 92:4218-4223.